arrow
R

Roisin E. O'Cearbhaill

Memorial Sloan Kettering Cancer Center
H指数:38
被引数:8,179

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer

卵巢癌中mirvetuximab soravtansine-gynx引起的白内障发生率及临床特征:一种未被充分认识的副作用

2026-04-250
PRE
Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer

基于NRG GY017的局部晚期宫颈癌免疫治疗联合化疗放射治疗中的影像引导近距离放射治疗质量保证研究

2026-01-011
OAAI
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review

美国食品药品监督管理局关于聚腺苷二磷酸核糖聚合酶抑制剂在卵巢癌中批准情况的更新:妇科肿瘤学会临床实践综述

2025-12-100
PRE
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer

一项关于尼洛替尼与卵巢癌新诊断患者新辅助及术后化疗联合应用的试点研究

2025-10-310
PRE
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

一项关于紫杉醇/卡铂/二甲双胍与紫杉醇/卡铂/安慰剂作为可测量病灶的III期或IVA期、IVB期或复发性子宫内膜癌初始治疗方案的比较研究:一项NRG oncology/GOG研究

2025-04-011
OAAI
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate

晚期卵巢癌患者接受抗FOLR1抗体药物偶联物治疗后的临床结局

2025-04-010
PRE
Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva

人乳头瘤病毒阴性外阴浸润性鳞状细胞癌的分子及微环境景观

2025-02-010
PRE
Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary

口服孕激素拮抗剂onapristone extended-release联合anastrozole治疗孕激素受体阳性的复发性成年型卵巢颗粒细胞瘤的篮子研究

2025-01-010
PRE
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ ENGOT-OV26/GOG-3012 trial

新诊断晚期卵巢癌患者的尼拉帕尼一线维持治疗: PRIMA/ ENGOT-OV26/GOG-3012试验的最终总生存期结果

2024-11-012
OAAI
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
2024-04-234
OAAI
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary

随访3.5年时的无进展生存期和安全性: 对新诊断卵巢癌患者进行尼拉帕尼维持治疗的3期PRIMA/ENGOT-OV26/GOG-3012随机试验的结果-简明语言总结

2024-03-191
OAAI
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

随访3.5年时的无进展生存期和安全性: 对新诊断卵巢癌患者进行尼拉帕尼维持治疗的3期PRIMA/ENGOT-OV26/GOG-3012随机试验的结果

2023-08-0141
OA
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

靶向间皮素的T细胞受体融合构建细胞治疗难治性实体瘤: 1/2期试验中期结果

2023-07-2727
OAAI
Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
2023-07-011
PRE
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
2023-06-08246
OA